Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CAR-T > FAP > FAP-C52H3

Cynomolgus FAP Protein, His Tag, active dimer (MALS verified)

  • Synonym
    FAP,FAPalpha,SIMP,Seprase,APCE
  • Source
    Cynomolgus FAP, His Tag (FAP-C52H3) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Asp 760 (Accession # XP_005573377.1).
    Predicted N-terminus: His
  • Molecular Characterization
    Online(Leu 26 - Asp 760) XP_005573377.1

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 90.8 kDa. The protein migrates as 85-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Cynomolgus FAP, His Tag (Cat. No. FAP-C52H3) SDS-PAGE gel

Cynomolgus FAP, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Cynomolgus FAP, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus FAP, His Tag (Cat. No. FAP-C52H3) is more than 90% and the molecular weight of this protein is around 182-223 kDa verified by SEC-MALS.

Bioactivity-ELISA
Cynomolgus FAP, His TagCynomolgus FAP, His Tag (Cat. No. FAP-C52H3) ELISA bioactivity

Immobilized Cynomolgus FAP, His Tag (Cat. No. FAP-C52H3) at 5 μg/mL (100 μL/well) can bind Anti-FAP Antibody, Mouse IgG2a (FAP5) with a linear range of 0.2-13 ng/mL (QC tested).

Bioactivity

Measured by its ability to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4-methylcoumarin (Z-GP-AMC) to Z-Gly-Pro and 7-amino-4-methylcoumarin (AMC). The specific activity is >7500 pmol/min/μg (QC tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-FAP Antibody, Mouse IgG2a (FAP5) captured on CM5 chip via anti-mouse antibodies surface can bind Cynomolgus FAP, His Tag (Cat. No. FAP-C52H3) with an affinity constant of 3.10 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

  • Background
    FAP (also known as seprase) is a Type II transmembrane serine protease. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences. Degrade also gelatin, heat-denatured type I collagen. Also has dipeptidyl peptidase activity, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro. The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $380.00

Price(USD) : $2750.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:7 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message